Silo Pharma regains Nasdaq minimum bid price compliance
Silo Pharma announced it regained compliance with Nasdaq's minimum closing bid price requirement as of June 17, 2026, resolving a listing qualification matter. The company continues trading on the Nasdaq Capital Market while advancing its lead PTSD drug candidate SPC-15 toward clinical trials.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
GET FREE KEY — 10,000 calls/day